IC
VERV

Ikarian Capital’s Verve Therapeutics VERV Stock Holding History

Ikarian Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41,300
Closed -$576K – 178
2023
Q4 		$576K Buy
41,300
+38,887
+1,612% +$482K 0.05% 114
2023
Q3 		$3.2M Buy
+2,413
New +$38.9K 0.38% 65

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ikarian Capital's VERV Position: Q2 2025 in Review

Ikarian Capital sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 358,393 shares — an estimated $1.64M sold.

Ikarian Capital first reported a position in VERV in Q3 2024 and held it in 3 quarters. The position peaked at $1.64M in Q1 2025. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Ikarian Capital reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 358,393 Verve Therapeutics shares in Q2 2025, an estimated $1.64M.
  • Ikarian Capital first reported a position in Verve Therapeutics in Q3 2024 and held it in 3 quarters.
  • Ikarian Capital's Verve Therapeutics position peaked at $1.64M in Q1 2025.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.